Literature DB >> 21444708

Gentian violet exhibits activity against biofilms formed by oral Candida isolates obtained from HIV-infected patients.

Rana S Traboulsi1, Pranab K Mukherjee, Jyotsna Chandra, Robert A Salata, Richard Jurevic, Mahmoud A Ghannoum.   

Abstract

The effect of gentian violet against Candida albicans and non-Candida albicans biofilms formed on polymethylmethacrylate strips was evaluated using a dry weight assay and confocal laser scanning microscopy. The ability of gentian violet to inhibit Candida albicans germination was also assessed. Gentian violet activity against Candida biofilms was demonstrated by a reduction in dry weight, disruption of biofilm architecture, and reduced biofilm thickness. Additionally, gentian violet inhibited Candida germination in a concentration-dependent manner.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21444708      PMCID： PMC3101405          DOI： 10.1128/AAC.01601-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  In vitro growth and analysis of Candida biofilms.

Authors:  Jyotsna Chandra; Pranab K Mukherjee; Mahmoud A Ghannoum
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

2.  Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins.

Authors:  D M Kuhn; T George; J Chandra; P K Mukherjee; M A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 3.  Oropharyngeal candidiasis in the era of antiretroviral therapy.

Authors:  George R Thompson; Payal K Patel; William R Kirkpatrick; Steven D Westbrook; Deborah Berg; Josh Erlandsen; Spencer W Redding; Thomas F Patterson
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2010-02-13

4.  Oral candidiasis and oral yeast carriage among institutionalised South African paediatric HIV/AIDS patients.

Authors:  Elaine Blignaut
Journal:  Mycopathologia       Date:  2007-02-12       Impact factor: 2.574

5.  Oral manifestations of HIV/AIDS in clients attending TASO clinics in Uganda.

Authors:  J F Tirwomwe; C M Rwenyonyi; L M Muwazi; B Besigye; F Mboli
Journal:  Clin Oral Investig       Date:  2007-05-03       Impact factor: 3.573

6.  Oral biofilm architecture on natural teeth.

Authors:  Vincent Zijnge; M Barbara M van Leeuwen; John E Degener; Frank Abbas; Thomas Thurnheer; Rudolf Gmür; Hermie J M Harmsen
Journal:  PLoS One       Date:  2010-02-24       Impact factor: 3.240

7.  The effect of gentian violet on virulent properties of Candida albicans.

Authors:  Su Ying; Sun Qing; Li Chunyang
Journal:  Mycopathologia       Date:  2009-11-24       Impact factor: 2.574

8.  Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols.

Authors:  Pranab K Mukherjee; Jyotsna Chandra; Duncan M Kuhn; Mahmoud A Ghannoum
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

Review 9.  Prevention of Chagas' disease resulting from blood transfusion by treatment of blood: toxicity and mode of action of gentian violet.

Authors:  R Docampo; S N Moreno; F R Gadelha; W de Souza; F S Cruz
Journal:  Biomed Environ Sci       Date:  1988-12       Impact factor: 3.118

10.  Parenteral lipid emulsion induces germination of Candida albicans and increases biofilm formation on medical catheter surfaces.

Authors:  Kim Swindell; Ali Abdul Lattif; Jyotsna Chandra; Pranab K Mukherjee; Mahmoud A Ghannoum
Journal:  J Infect Dis       Date:  2009-08-01       Impact factor: 5.226
View more
  4 in total

Review 1.  Gentian violet: a 19th century drug re-emerges in the 21st century.

Authors:  Alexander M Maley; Jack L Arbiser
Journal:  Exp Dermatol       Date:  2013-12       Impact factor: 3.960

Review 2.  Candida Biofilms: Development, Architecture, and Resistance.

Authors:  Jyotsna Chandra; Pranab K Mukherjee
Journal:  Microbiol Spectr       Date:  2015-08

3.  Topical gentian violet compared with nystatin oral suspension for the treatment of oropharyngeal candidiasis in HIV-1-infected participants.

Authors:  Pranab K Mukherjee; Huichao Chen; Lauren L Patton; Scott Evans; Anthony Lee; Johnstone Kumwenda; James Hakim; Gaerolwe Masheto; Frederick Sawe; Mai T Pho; Kenneth A Freedberg; Caroline H Shiboski; Mahmoud A Ghannoum; Robert A Salata
Journal:  AIDS       Date:  2017-01-02       Impact factor: 4.177

4.  Heat shock protein 90 inhibitors repurposed against Entamoeba histolytica.

Authors:  Dea Shahinas; Anjan Debnath; Christan Benedict; James H McKerrow; Dylan R Pillai
Journal:  Front Microbiol       Date:  2015-04-28       Impact factor: 5.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.